Innovative ETFs Content Hub Invesco’s Rene Reyna on Biotech’s Rally and the Potential for Future Growth By Elle Caruso FitzgeraldAugust 19, 2022
Nasdaq Investment Intelligence Content Hub Pfizer Biohaven Acquisition Sparks Hope of More Biotech M&A By Tom LydonMay 12, 2022
Nasdaq Investment Intelligence Content Hub Battered Biotech Space Now Unbelievably Inexpensive By Tom LydonMay 6, 2022
Nasdaq Investment Intelligence Content Hub Cap-Weighting Crucial When Indexing Biotech By James ComtoisJanuary 25, 2022
Nasdaq Investment Intelligence Content Hub Biotech Firms Partner to Advance Therapeutic Medicine By James ComtoisJanuary 13, 2022
Innovative ETFs Content Hub An ETF to Capture Promising Biotech Innovators By Max ChenJanuary 12, 2022
Nasdaq Investment Intelligence Content Hub Biotech Stocks and ETFs Can Get Their Grooves Back By Tom LydonJanuary 11, 2022
ETF Education Content Hub Expect More Biotech Consolidation Activity in 2022 By Tom LydonDecember 14, 2021
Innovative ETFs Content Hub Moderna’s Omicron Booster Strategy Lifts Biotechnology ETFs By Max ChenNovember 29, 2021
ETF Education Content Hub Position for Biotech Rebound With Quality Names By Tom LydonOctober 19, 2021
Innovative ETFs Content Hub An ETF to Watch for Amidst the Vaccine Push By Ben HernandezAugust 6, 2021
Nasdaq Investment Intelligence Content Hub New Biotechnology ETF Could Be a Stellar Second Half Idea By Tom LydonJuly 1, 2021
Innovative ETFs Content Hub A Biotech ETF to Track Nasdaq’s Industry-Setting Benchmark By Max ChenJune 30, 2021
Innovative ETFs Content Hub The Biotech Trek: A Short History from 1993 to 2021 By Max ChenJune 29, 2021
Nasdaq Investment Intelligence Content Hub New Invesco ETF Joins the Gold Standard of Biotech Benchmarks By Tom LydonJune 11, 2021
